Core Viewpoint - Guangzhou Pharmaceutical Co., Ltd. (referred to as "Guangzhou Medicine") will be listed on the National Equities Exchange and Quotations (NEEQ) starting May 20, 2025, after previously attempting an IPO in Hong Kong without success [1][2]. Group 1: Company Overview - Guangzhou Medicine, established in 1951, is the largest pharmaceutical distribution company in South China, engaging in wholesale and retail of pharmaceuticals, including Western medicine, traditional Chinese medicine, and medical devices, with over 1,700 employees [2]. - White Cloud Mountain Pharmaceutical Group Co., Ltd. (referred to as "White Cloud Mountain") holds a 90.92% stake in Guangzhou Medicine, making it the controlling shareholder [2]. Group 2: Financial Performance - Guangzhou Medicine's revenue for 2023 and 2024 is projected to be 52.591 billion yuan and 54.605 billion yuan, respectively, with net profits of 649 million yuan and 578 million yuan [2]. - In contrast, White Cloud Mountain reported a decline in net profit for 2024, reaching 2.835 billion yuan, a decrease of 30.09% year-on-year, with total revenue of 74.993 billion yuan, down 0.69% [4]. Group 3: Strategic Decisions - The decision to list Guangzhou Medicine on the NEEQ follows the termination of its H-share listing plans due to changes in market conditions and the expiration of regulatory approvals [2]. - White Cloud Mountain stated that the new listing will not adversely affect its financial status or operational results, as Guangzhou Medicine will remain a consolidated subsidiary [3]. Group 4: Challenges and Considerations - White Cloud Mountain's financial difficulties, including significant impairment provisions totaling approximately 471 million yuan, may impact Guangzhou Medicine's future fundraising efforts [5]. - The company faces challenges from industry policy changes and intense market competition, raising questions about its plans for product structure optimization and cost control [5].

当下，北交所已经成为很多拟上市企业的首选地。相较于沪深交易所，北交所上市门槛没有那么 高，上市周期更短，费用也更低， 2024年 平均发行费用为2510万元左右。 而且，近期网上流传的IPO小作文也提到， 北交所会成为未来主要的上市通道： 不过，虽然北交所门槛较低，但也不是企业想上就能上的。 2024年全年，北交所共有23家新上市公 司， 这23家公司的 2022年度 扣非净利润平均数为 4386.85万元 ，中位数为 3994.44万元 ； 2023 年度 扣非净利润平均数为 6141.66万元 ，中位数为 4748.35万元 。这也说明北交所的上市条件是逐 年递增的，企业上市的不确定性也在增大。 为了帮助大家更详细地掌握 北交所最新上市政策、上市流程、审核重点关注 等方面问题，抓住政策 红利，提高北交所上市的成功率， 梧桐课堂 特邀拥有18年从业经验的资深保荐代表人 肖鹏 老师， 为我们详解 《北交所上市全解析专题》（限时7折最后1天） 。 北交所上市全解析专题 12节课，时长5小时5分钟 第二部分内容围绕新三板展开，主要讲解了四个方面内容，包括当前新三板发展概况、新三板挂 牌基本要求和财务指标、挂牌程序 ...